adult; advisory committee; article; blood clot; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; drug safety; groups by age; health care personnel; human; incidence; infection control; infection rate; medical society; patient preference; platelet count; risk benefit analysis; side effect/si [Side Effect]; single drug dose; thromboembolism/si [Side Effect]; United Kingdom; vaccination; ad26.cov2.s vaccine/dt [Drug Therapy]; tozinameran/dt [Drug Therapy]; vaxzevria/ae [Adverse Drug Reaction]; vaxzevria/dt [Drug Therapy]; ad 26cov 2s vaccine